Home
University & Research Institutions

Sector: University & Research Institutions

Your guide to synthetic drug royalty dealmaking

Selling revenue streams is an increasingly important way of monetising pharma innovations

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

France Brevets’ public sector links hindered monetisation efforts, says CEO

As the sovereign patent fund closes down, CEO Didier Patry shares his thoughts with IAM readers on the organisation’s work over the past decade

Latest content

Pharma should make good use of the UPC from the beginning, says Bayer’s head of IP

There are a lot of potential benefits to the new system, but we need to integrate it into our strategies to make sure it works, explains Joerg Thomaier

11 August 2021

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

The company is hoping to raise cash to help expand its purchasing power when acquiring pharmaceuticals revenue streams

05 August 2021

Ofinno's Honda and Xiaomi deals point to strong 5G patent secondary market

The Virginia-based R&D outfit has made a string of sales to big names in consumer tech over recent months, with Samsung another prominent customer

26 July 2021

UK Supreme Court quashes £220 million third-party lawsuit against patent litigant

Country’s National Health Service fails to overturn rules on damages sought by healthcare providers affected by failed enforcement

07 July 2021

Everything you need to know about SCOTUS’ Minerva ruling on assignor estoppel

In a 5-4 decision the court’s justices significantly narrowed the scope of the doctrine that prevents assignors from challenging patents in court.

01 July 2021

University and Big Pharma JV’s $145 million take-off is a big boost for tech transfer dealmaking

Apollo Therapeutics is an innovative biotech formed by three UK universities and three major companies, with a promising model for creating and monetising life sciences IP

29 June 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of.

17 June 2021

The IP dangers in life sciences collaborations and how to avoid them

Partnership agreements are a growing part of the biopharma R&D process, so anticipating potential pitfalls in such arrangements is vital

14 June 2021

China bill moving through US Senate would create list of ‘IP violators’

The Strategic Competition Act of 2021 could also see increased use of sanctions to combat IP theft

28 April 2021

TRIPS covid vaccine IP waiver proposal fails to address crucial questions

President Biden and other leaders are coming under pressure to agree a suspension of IP rights, but a key point has been missed

20 April 2021

Unlock unlimited access to all IAM content